Please assess the completion status of the following clinical trial:

Trial Title: Biatain Ibu vs. Biatain in Painful Chronic Venous Leg Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>= 18 years of age~* Chronic venous leg ulcer on the lower leg~* Ulcer duration \>= 8 weeks~* Pain intensity in study ulcer at least 4 on an 11-point numerical box scale (NBS): 0= no pain, 10= worst possible pain~* Exudate level moderate to high~* Ulcer size min 1.6 cm and max 11 cm in any direction~* Ankle/brachial index \>= 0.8~* Treated with moist wound healing during the past 2 weeks prior to inclusion~* Adequate compression therapy during the past 2 weeks prior to inclusion~* The patient is cognitive capable of evaluating his/her pain relief and pain intensity~* The patient is able to understand the treatment and is willing to comply with the treatment regimen.~* The patient is able to complete the patient diary~* The patient is willing and able to give written informed consent~Exclusion Criteria:~* Painful ulcers that have been treatment resistant to analgesics for the past 6 months or more~* Pregnant or lactating women~* Known and verified hypersensitivity to any content of the products used in this investigation~* Local infection (bacterial imbalanced wound) in the study ulcer~* Clinical infection in the study ulcer~* Diseases: Vasculitis, erysipelas and cellulitis of the peri-ulcer skin~* The investigator considers the patient not eligible~* Diseases and conditions where ibuprofen or other analgesics are contraindicated (including known hypersensitivity to Aspirin (acetylsalicylic acid) or other analgesics, especially associated with a history of asthma, rhinitis or urticaria)~* Diabetes~* Use of per need medication for the past 3 days~* Concomitant treatment with systemic antibiotics other than nitrofurantoin~* Concomitant treatment with systemic corticosteroids (more than 10 mg/day prednisolon or equivalent) or other immunosuppressants within 1 month prior to inclusion~* Concomitant treatment with cancer chemotherapeutics~* Concomitant participation in other studies~* Previous participation in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biatain Ibu (Type: EXPERIMENTAL): Biatain Ibu
- Biatain (Type: ACTIVE_COMPARATOR): Biatain

Based on this trial design, predict the completion outcome and termination type (if applicable).